Efficacy and Safety of Encaleret Compared to Standard of Care in Participants With ADH1

Running, not enrolling · Phase 3

Conditions studied: Autosomal Dominant Hypocalcemia (ADH)

In brief

The primary purpose of the study is to understand the effectiveness, safety, and tolerability of encaleret when compared to standard of care (SoC) treatment in participants with Autosomal Dominant Hypocalcemia Type 1 (ADH1).

Key facts

Study ID
NCT05680818
Run by
Calcilytix Therapeutics, Inc., a BridgeBio company
People needed
67
Starts
2023-01-06
Expected to finish
2029-08-01
Last updated by the study team
2026-07-29

Who can join

Age: 16 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.